2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-120855
    CCG-100602 1207113-88-9 99.29%
    CCG-100602 is a specific inhibitor of myocardin-related transcription factor A/serum response factor (MRTF-A/SRF) signaling. CCG-100602 specifically block MRTF-A nuclear localization and thus inhibit the fibrogenic transcription factor SRF.
    CCG-100602
  • HY-12798C
    AR-13503 2309668-15-1 98.21%
    AR-13503 (AR-13324 M1 metabolite) is the hydrolytic metabolite of AR-13324 mesylate. AR-13324 is a ROCK kinase and PKC inhibitor with anti-angiogenic and retinal health-improving effects, showing potential for use in retinal disease research.
    AR-13503
  • HY-143219
    SS-Inclisiran sodium 98.88%
    SS-Inclisiran (sodium) is a sense strand of Inclisiran. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9.
    SS-Inclisiran sodium
  • HY-15849A
    LP-533401 hydrochloride 1040526-12-2 98.02%
    LP-533401 hydrochloride is a tryptophan hydroxylase 1 inhibitor that regulates serotonin production in the gut.
    LP-533401 hydrochloride
  • HY-160186
    20-SOLA 98.76%
    20-SOLA is an orally active 20-HETE antagonist. 20-SOLA greatly ameliorates changes in blood pressure and renal injury associated with a Streptozotocin (STZ) (HY-13753)-diabetic mouse model. 20-SOLA facilitates the restoration of coronary collateral growth (CCG) after ischemic injury. 20-SOLA can be studied for research in cardiovascular diseases and diabetes.
    20-SOLA
  • HY-N0060A
    Ferulic acid sodium 24276-84-4 99.87%
    Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.
    Ferulic acid sodium
  • HY-P0203B
    β-CGRP (mouse) 99.77%
    β-CGRP (mouse) is a calcitonin gene-related peptide that induces vasodilation. β-CGRP (mouse) can be utilized in cardiovascular, pro-inflammatory, migraine and metabolic research.
    β-CGRP (mouse)
  • HY-P1136B
    TAT-Gap19 1507930-54-2 99.47%
    TAT-Gap19, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 traverses the blood-brain barrier and alleviate liver fibrosis in mice.
    TAT-Gap19
  • HY-101404A
    L-Homocysteine thiolactone hydrochloride 31828-68-9 99.99%
    L-Homocysteine thiolactone hydrochloride is an intramolecular thioester of Homocysteine. Homocysteine thiolactone hydrochloride prevents translational incorporation of homocysteine into proteins. L-Homocysteine thiolactone hydrochloride can induce elevated HHcy (hyperhomocysteinemia) in mice.
    L-Homocysteine thiolactone hydrochloride
  • HY-112248A
    HAMI 3379 1245653-57-9
    HAMI 3379 is a potent and selective CysLT2 receptor antagonist. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation.
    HAMI 3379
  • HY-N0666S8
    L-Aspartic acid-d3 3842-25-9 ≥99.0%
    L-Aspartic acid-d3 is the deuterium labeled L-Aspartic acid. L-Aspartic acid is is an amino acid, shown to be a suitable proagent for colon-specific agent deliverly.
    L-Aspartic acid-d3
  • HY-N0830S5
    Palmitic acid-d3 75736-53-7 ≥98.0%
    Palmitic acid-d3 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants. PA can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells.
    Palmitic acid-d3
  • HY-W010696
    Reverse T3 5817-39-0
    Reverse T3 is a thyroid hormone that can be generated by deiodination of the prohormone thyroxine. Reverse T3 inhibits the increase of sodium current generated by other thyroid hormone analogs in neonatal rat myocytes.
    Reverse T3
  • HY-N0852
    Benzoylpaeoniflorin 38642-49-8 99.35%
    Benzoylpaeoniflorin, a natural product from Chinese paeony root, has the potential for coronary heart disease by decreasing apoptosis.
    Benzoylpaeoniflorin
  • HY-W001583
    Manganese(salen) chloride 53177-12-1
    Manganese(salen) chloride (EUK-8), a superoxide dismutase and catalase mimetic, is an antioxidant with oxyradical scavenging properties. Manganese(salen) chloride ameliorates acute lung injury in endotoxemic swine.
    Manganese(salen) chloride
  • HY-W011235
    Norfluoxetine hydrochloride 57226-68-3 99.58%
    Norfluoxetine hydrochloride is an active N-demethylated metabolite of Fluoxetine. Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor that is metabolized to Norfluoxetine hydrochloride by cytochrome P450 (CYP) 2D6, CYP2C19, and CYP3A4. Norfluoxetine hydrochloride inhibits 5-HT uptake and inhibits CaV3.3 T current (IC50 = 5 μM). Norfluoxetine hydrochloride has anticonvulsant activity.
    Norfluoxetine hydrochloride
  • HY-10333
    BMS-690514 859853-30-8 99.68%
    BMS-690514 is a potent and orally active inhibitor of EGFR and VEGFR; has IC50s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively.
    BMS-690514
  • HY-12090
    Anacetrapib 875446-37-0 99.25%
    Anacetrapib is a potent CETP inhibitor, with IC50s of 7.9±2.5 nM and 11.8±1.9 nM for rhCETP and C13S CETP mutant, respectively.
    Anacetrapib
  • HY-100115
    TA-02 1784751-19-4 99.85%
    TA-02, an analog of SB 203580 (HY-10256), is a p38 MAPK inhibitor with an IC50 of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295).
    TA-02
  • HY-103310
    MRS1845 544478-19-5 99.46%
    MRS1845 is a selective store-operated calcium (SOC) channel inhibitor with an IC50 of 1.7 μM. MRS1845 is an ORAI1 inhibitor. MRS1845 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MRS1845
Cat. No. Product Name / Synonyms Application Reactivity